In the field of cancer therapy, lipid nanocapsules based on a core-shell structure are promising vehicles for the delivery of hydrophobic drugs such as docetaxel. The main aim of this work was to evaluate whether docetaxel-loaded lipid nanocapsules improved the anti-tumor effect of free docetaxel in breast cancer cells. Three docetaxel-loaded lipid nanocapsules were synthesized by solvent displacement method. Cytotoxic assays were evaluated in breast carcinoma (MCF-7) cells treated by the sulforhodamine B colorimetric method. Cell cycle was studied by flow cytometry and Annexin V-FITC, and apoptosis was evaluated by using propidium iodide assays. The anti-proliferative effect of docetaxel appeared much earlier when the drug was encapsulated in lipid nanoparticles than when it was free. Docetaxel-loaded lipid nanocapsules significantly enhanced the decrease in IC 50 rate, and the treated cells evidenced apoptosis and a premature progression of the cell cycle from G(1) to G(2)-M phase. The chemotherapeutic effect of free docetaxel on breast cancer cells is improved by its encapsulation in lipid nanocapsules. This approach has the potential to overcome some major limitations of conventional chemotherapy and may be a promising strategy for future applications in breast cancer therapy.
References
[1]
Ferlay, J.; Shin, H.R.; Bray, F.; Forman, D.; Mathers, C.; Parkin, D.M. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer 2010, 127, 2893–2917.
[2]
Jemal, A.; Bray, F.; Center, M.M.; Ferlay, J.; Ward, E.; Forman, D. Global cancer statistics. CA Cancer J. Clin 2011, 61, 69–90.
[3]
Verma, S.; Lavasani, S.; Mackey, J.; Pritchard, K.; Clemons, M.; Dent, S.; Latreille, J.; Lemieux, J.; Provencher, L.; Verma, Sh.; et al. Optimizing the management of HER2-positive early breast cancer: The clinical reality. Curr. Oncol. 2010, 17, 20–33.
[4]
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 2005, 365, 1687–1717.
[5]
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Polychemotherapy for early breast cancer: An overview of the randomised trials. Lancet 1998, 352, 930–942.
[6]
Qin, Y.Y.; Li, H.; Guo, X.J.; Ye, X.F.; Wei, X.; Zhou, Y.H.; Zhang, X.J.; Wang, C.; Qian, W.; Lu, J.; et al. Adjuvant chemotherapy, with or without taxanes, in early or operable breast cancer: A meta-analysis of 19 randomized trials with 30698 patients. PLoS One 2011, 6, doi:10.1371/journal.pone.0026946.
[7]
Peer, D.; Karp, J.M.; Hong, S.; Farokhzad, O.C.; Margalit, R.; Langer, R. Nanocarriers as an emerging platform for cancer therapy. Nat. Nanotechnol 2007, 2, 751–760.
Ma, Y.; Zheng, Y.; Zeng, X.; Jiang, L.; Chen, H.; Liu, R.; Huang, L.; Mei, L. Novel docetaxel-loaded nanoparticles based on PCL-Tween 80 copolymer for cancer treatment. Int. J. Nanomed 2011, 6, 2679–2688.
[10]
Blanco, E.; Hsiao, A.; Mann, A.P.; Landry, M.G.; Meric-Bernstam, F.; Ferrari, M. Nanomedicine in cancer therapy: Innovative trends and prospects. Cancer Sci 2011, 102, 1247–1252.
[11]
Duncan, R. The dawning era of polymer therapeutics. Nat. Rev. Drug Discov 2003, 2, 347–360.
[12]
Strebhardt, K.; Ullrich, A. Paul Ehrlich’s magic bullet concept: 100 years of progress. Nat. Rev 2008, 8, 473–480.
[13]
Boulaiz, H.; Alvarez, P.J.; Ramirez, A.; Marchal, J.A.; Prados, J.; Rodríguez-Serrano, F.; Perán, M.; Melguizo, C.; Aranega, A. Nanomedicine: Application areas and development prospects. Int. J. Mol. Sci 2011, 12, 3303–3321.
[14]
Maeda, H. The enhanced permeability and retention (EPR) effect in tumor vasculature: The key role of tumor-selective macromolecular drug targeting. Adv. Enzym. Regul 2001, 41, 189–207.
[15]
Couvreur, P.; Barratt, G.; Fattal, E.; Legrand, P.; Vauthier, C. Nanocapsule technology: A review. Crit. Rev. Ther. Drug Carrier Syst 2002, 19, 99–134.
[16]
Sánchez-Moreno, P.; Ortega-Vinuesa, J.L.; Martín-Rodríguez, A.; Boulaiz, H.; Marchal, J.A.; Peula-García, J.M. Characterization of different functionalized lipidic nanocapsules as potential drug carriers. Int. J. Mol. Sci 2012, 13, 2405–2424.
[17]
Immordino, M.L.; Brusa, P.; Arpicco, S.; Stella, B.; Dosio, F.; Cattel, L. Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing docetaxel. J. Control. Release 2003, 91, 417–429.
[18]
Earhart, R.H. Docetaxel (taxotere): Preclinical and general clinical information. Semin. Oncol 1999, 26, 8–13.
[19]
Verweij, J. Docetaxel (taxotere？): A new anti-cancer drug with promising potential? Br. J. Cancer 1994, 70, 183–184.
[20]
Piccart, M.J.; di Leo, A. Future perspectives of docetaxel (taxotere) in front-line therapy. Semin. Oncol 1997, 24, S10-27–S10-33.
[21]
Lee, S.W.; Yun, M.H.; Jeong, S.W.; In, C.H.; Kim, J.Y.; Seo, M.H.; Pai, C.M.; Kim, S.O. Development of docetaxel-loaded intravenous formulation, Nanoxel-PM？ using polymer-based delivery system. J. Control. Release 2011, 155, 262–271.
[22]
Weiszhár, Z.; Czúcz, J.; Révész, C.; Rosivall, L.; Szebeni, J.; Rozsnyay, Z. Complement activation by polyethoxylated pharmaceutical surfactants: Cremophor-EL, Tween-80 and Tween-20. Eur. J. Pharm. Sci 2011, 45, 492–498.
[23]
Zhao, M.; Su, M.; Lin, X.; Luo, Y.; He, H.; Cai, C.; Tang, X. Evaluation of docetaxel-loaded intravenous lipid emulsion: Pharmacokinetics, tissue distribution, antitumor activity, safety and toxicity. Pharm. Res 2010, 27, 1687–1702.
[24]
Gao, K.; Sun, J.; Liu, K.; Liu, X.; He, Z. Preparation and characterization of a submicron lipid emulsion of docetaxel: Submicron lipid emulsion of docetaxel. Drug Dev. Ind. Pharm 2008, 34, 1227–1237.
[25]
Sahu, A.; Kasoju, N.; Goswami, P.; Bora, U. Encapsulation of curcumin in Pluronic block copolymer micelles for drug delivery applications. J. Biomater. Appl 2011, 25, 619–639.
[26]
Ray, S.D. Potential aspects of chitosan as pharmaceutical excipient. Acta Pol. Pharm 2011, 68, 619–622.
[27]
Wasan, K.M. The biological functions of lipid excipients and the implications for pharmaceutical products development. J. Pharm. Sci 2009, 98, 379–382.
[28]
Anbharasi, V.; Cao, N.; Feng, S.S. Doxorubicin conjugated to d-alpha-tocopheryl polyethylene glycol succinate and folic acid as a prodrug for targeted chemotherapy. J. Biomed. Mater. Res. A 2010, 94, 730–743.
[29]
Florence, A.T.; Hussain, N. Transcytosis of nanoparticle and dendrimer delivery systems: Evolving vistas. Adv. Drug Deliv. Rev 2001, 50, 69–89.
[30]
Sandri, G.; Bonferoni, M.C.; Rossi, S.; Ferrari, F.; Gibin, S.; Zambito, Y.; di Colo, G.; Caramella, C. Nanoparticles based on N-trimethylchitosan: Evaluation of absorption properties using in vitro (Caco-2 cells) and ex vivo (excised rat jejunum) models. Eur. J. Pharm. Biopharm 2007, 65, 68–77.
[31]
Lozano, M.V.; Torrecilla, D.; Torres, D.; Vidal, A.; Dominguez, F.; Alonso, M.J. Highly efficient system to deliver taxanes into tumor cells: Docetaxel-loaded chitosan oligomer colloidal carriers. Biomacromolecules 2008, 9, 2186–2193.
[32]
Hafner, A.; Lovric, J.; Voinovich, D.; Filipovic-Grcic, J. Melatonin-loaded lecithin/chitosan nanoparticles: Physicochemical characterization and permeability through Caco-2 cell monolayers. Int. J. Pharm 2009, 381, 205–213.
[33]
Vonarbourg, A.; Passirani, C.; Saulnier, P.; Benoit, J.P. Parameters influencing the stealthiness of colloidal drug delivery systems. Biomaterials 2006, 27, 4356–4373.
[34]
Beduneau, A.; Saulnier, P.; Benoit, J.P. Active targeting of brain tumors using nanocarriers. Biomaterials 2007, 28, 4947–4967.
[35]
Youm, I.; Yang, X.Y.; Murowchick, J.B.; Youan, B.B. Encapsulation of docetaxel in oily core polyester nanocapsule intended for breast cancer therapy. Nanoscale Res. Lett 2011, 6, doi:10.1186/1556-276X-6-630.
[36]
Li, P.Y.; Lai, P.S.; Hung, W.C.; Syu, W.J. Poly(l-lactide)-vitamin E TPGS nanoparticles enhanced the cytotoxicity of doxorubicin in drug-resistant MCF-7 breast cancer cells. Biomacromolecules 2010, 11, 2576–2582.
[37]
Montero, A.; Fossella, F.; Hortobagyi, G.; Valero, V. Docetaxel for treatment of solid tumours: A systematic review of clinical data. Lancet Oncol 2005, 6, 229–239.
[38]
Chadderton, A.; Villeneuve, D.J.; Gluck, S.; Kirwan-Rhude, A.F.; Gannon, B.R.; Blais, D.E.; Parissenti, A.M. Role of specific apoptotic pathways in the restoration of paclitaxel-induced apoptosis by valspodar in doxorubicin-resistant MCF-7 breast cancer cells. Breast Cancer Res. Treat 2000, 59, 231–244.
[39]
Marchal, J.A.; Nú？ez, M.C.; Suárez, I.; Díaz-Gavilán, M.; Gómez-Vidal, J.A.; Boulaiz, H.; Rodríguez-Serrano, F.; Gallo, M.A.; Espinosa, A.; Aránega, A.; et al. A synthetic uracil derivative with antitumor activity through decreasing cyclin D1 and Cdk1, and increasing p21 and p27 in MCF-7 cells. Breast Cancer Res. Treat 2007, 105, 237–246.
[40]
Hernández-Vargas, H.; Palacios, J.; Moreno-Bueno, G. Molecular profiling of docetaxel cytotoxicity in breast cancer cells: Uncoupling of aberrant mitosis and apoptosis. Oncogene 2007, 26, 2902–2913.
[41]
Liu, D.; Liu, Z.; Wang, L.; Zhang, C.; Zhang, N. Nanostructured lipid carriers as novel carrier for parenteral delivery of docetaxel. Colloids Surf. B Biointerfaces 2011, 85, 262–269.
[42]
Sharma, R.I.; Welch, A.E.; Schweiger, L.; Craib, S.; Smith, T.A. [18F]Fluoro-2-deoxy-d-glucose incorporation by MCF-7 breast tumour cells in vitro is modulated by treatment with tamoxifen, doxorubicin, and docetaxel: Relationship to chemotherapy-induced changes in ATP content, hexokinase activity, and glucose transport. Int. J. Mol. Imaging 2011, 2011, doi:10.1155/2011/874585.
[43]
Ghawanmeh, T.; Thunberg, U.; Castro, J.; Murray, F.; Laytragoon-Lewin, N. MiR-34a expression, cell cycle arrest and cell death of malignant mesothelioma cells upon treatment with radiation, docetaxel or combination treatment. Oncology 2012, 10, 330–335.
[44]
Villalobos, M.; Olea, N.; Brotons, J.A.; Olea-Serrano, M.F.; Ruiz de Almodovar, J.M.; Pedraza, V. The E-Screen assay: A comparison of different MCF-7 cell stocks. Environ. Health Perspect 1995, 9, 844–849.
